Versiti Blood Health Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
VERSITI WISCONSIN, INC. (VERSITI) IS A BLOOD HEALTH INNOVATOR WHICH ENHANCES LIVES THROUGH DISCOVERY, DIAGNOSIS AND TREATMENT. VERSITI EXPANDS THE FRONTIERS OF PATIENT HEALTH THROUGH THE INTEGRATION OF SCIENCE, MEDICINE AND SERVICE.
- Income
- $281.0 million
- Spending
- $263.6 million
- Spent on programs
- 87%
- Reserves
- 3.4 months of spending
- Largest source of income
- fees for its services, 81%
- Employees
- 1,342
- Volunteers
- 289
- Highest pay
- $1.7 million, president & ceo
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Good: 75 out of 100. Higher than 64% of charities in its peer group (health care, over $100m).
Reserves
20 of 35Spendable reserves would cover 3.4 months of spending.
Debt
10 of 20It owes 35% of what it owns.
Living within its means
15 of 15Income exceeded spending by 6% of income.
Income trend
15 of 15Income rose 19% on the year before.
Spending floor
15 of 1587% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 53% of charities in its peer group (health care, over $100m).
Independent board
25 of 2517 of 18 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (4)
- $58.4 million spent. VERSITI OPERATES THE COMPREHENSIVE CENTER FOR BLEEDING DISORDERS (CCBD) UNDER A FEDERAL SUBAWARD AGREEMENT OF THE SOCIAL SECURITY ACT, PROVIDING SPECIALIZED DIAGNOSIS, TREATMENT, AND SUPPORTIVE CARE TO PATIENTS WITH INHERITED AND ACQUIRED BLEEDING AND CLOTTING DISORDERS. AS PART OF VERSITI'S MISSION TO IMPROVE PATIENT OUTCOMES, CCBD DELIVERS COMPREHENSIVE CARE THROUGH A MULTIDISCIPLINARY TEAM OF HEMATOLOGISTS, NURSES, SOCIAL WORKERS, AND SPECIALIZED STAFF. IN 2024, CCBD PROVIDED CRITICAL SERVICES TO PATIENTS WITH BLEEDING DISORDERS AND THEIR FAMILIES, INCLUDING FOR HEMOPHILIA A AND B, VON WILLEBRAND DISEASE, AND OTHER RARE COAGULATION DISORDERS. CCBD PROVIDED 17,470 SPECIALTY PHARMACY PRODUCTS IN 2024 AND CONTINUES TO BE A FEDERALLY RECOGNIZED HEMOPHILIA TREATMENT CENTER (HTC). AS A (CONTINUED IN SCHEDULE O) COVERED ENTITY UNDER THE 340B DRUG DISCOUNT PROGRAM, VERSITI ACCESSES SPECIALTY PHARMACEUTICALS AT DISCOUNTED PRICING, PASSING SAVINGS ON TO PATIENTS AND REDUCING COSTS TO THE HEALTHCARE SYSTEM WHILE ENSURING PHARMACEUTICAL NET INCOME SUPPORTS PROGRAM ACTIVITIES INCLUDING PATIENT CARE, EDUCATION, SUPPORT SERVICES, AND APPROVED RESEARCH. VERSITI PROVIDES THESE SPECIALTY PHARMACY PRODUCTS TO HOME CARE PATIENTS AND HOSPITAL SYSTEMS, IMPROVING MEDICATION ACCESS AND ADHERENCE. THE CENTER'S COMPREHENSIVE SERVICES INCLUDE FACTOR REPLACEMENT THERAPY, PROPHYLACTIC TREATMENT PROTOCOLS, GENETIC COUNSELING, AND PATIENT EDUCATION PROGRAMS DESIGNED TO HELP INDIVIDUALS WITH BLEEDING DISORDERS LIVE FULL, ACTIVE LIVES. THROUGH SPECIALIZED EXPERTISE, FEDERAL PARTNERSHIP, AND COMPASSIONATE CARE, CCBD SERVES AS A PREMIER RESOURCE FOR BLEEDING DISORDER TREATMENT, IMPROVING OUTCOMES WHILE REDUCING HEALTHCARE COSTS FOR PATIENTS WITH THESE COMPLEX CONDITIONS.
- $47.2 million spent. VERSITI WISCONSIN RECRUITS VOLUNTEER BLOOD DONORS AND COLLECTS, PROCESSES, AND DISTRIBUTES BLOOD PRODUCTS AS PART OF ITS MISSION TO PROVIDE A SAFE AND RELIABLE BLOOD SUPPLY FOR HOSPITALS AND HEALTHCARE SYSTEMS ACROSS WISCONSIN. VERSITI'S COMPREHENSIVE BLOOD INVENTORY INCLUDES RED BLOOD CELLS, PLATELETS, PLASMA, AND SPECIALIZED PRODUCTS DESIGNED TO MEET PATIENT NEEDS. IN 2024, VERSITI WISCONSIN COLLECTED TOTAL RED BLOOD CELLS AND PLATELETS OF 152,765, SERVING 62 HOSPITALS. THE ORGANIZATION HOSTED 2,808 COMMUNITY BLOOD DRIVES, ENGAGING 56,626 VOLUNTEER DONORS WHO CONTRIBUTED TO VERSITI'S LIFESAVING MISSION. (CONTINUED IN SCHEDULE O)INNOVATION AND EMERGENCY RESPONSE: DURING 2024, VERSITI WISCONSIN PARTNERED WITH MILWAUKEE COUNTY TO LAUNCH AN INNOVATIVE EMS PREHOSPITAL WHOLE BLOOD TRANSFUSION PROGRAM FOR CRITICALLY INJURED TRAUMA PATIENTS, THE FIRST SUCH PARTNERSHIP IN WISCONSIN. COMMUNITY PARTNERSHIPS: AS A VITAL PARTNER IN PUBLIC HEALTH, VERSITI WISCONSIN PARTICIPATED IN THE #KNOWSCD SICKLE CELL DISEASE AWARENESS CAMPAIGN, THE WE GIVE BLOOD DRIVE PARTNERSHIP WITH ABBOTT AND THE BIG TEN CONFERENCE DURING THE 2024 FOOTBALL SEASON, AND THE ORGANIZATION'S VERSITI ON KING COMMUNITY CENTER CONDUCTED BLOOD TYPING EVENTS FOR 140 INDIVIDUALS, IDENTIFYING 43 POTENTIAL RO DONORS TO SUPPORT PATIENTS WITH SICKLE CELL DISEASE. INFRASTRUCTURE AND OPERATIONS: VERSITI WISCONSIN OPERATES DONOR CENTERS AND MOBILE COLLECTION UNITS THROUGHOUT THE STATE. IN 2024, THE ORGANIZATION COMPLETED 4 DONOR CENTER RENOVATIONS TO IMPROVE DONOR COMFORT, ENHANCE OPERATIONAL EFFICIENCY, AND EXPAND COLLECTION CAPACITY. THROUGH DEDICATED VOLUNTEER DONORS AND STRATEGIC COMMUNITY PARTNERSHIPS, VERSITI WISCONSIN MAINTAINS A ROBUST BLOOD SUPPLY THAT ENABLES HOSPITALS TO PROVIDE CRITICAL CARE, EMERGENCY SERVICES, AND LIFESAVING TREATMENTS TO PATIENTS THROUGHOUT THE REGION.
- $39.7 million spent. VERSITI RESEARCH ADVANCES SCIENTIFIC DISCOVERY AND PATIENT CARE THROUGH COMPREHENSIVE SUPPORT OF BLOOD-RELATED RESEARCH, EDUCATION, AND COMMUNITY ENGAGEMENT PROGRAMS. ROOTED IN ITS NONPROFIT MISSION, VERSITI ENABLES GROUNDBREAKING BLOOD RESEARCH WHILE FOSTERING THE NEXT GENERATION OF SCIENTISTS AND IMPROVING THE LIVES OF PATIENTS AFFLICTED BY BLOOD DISORDERS. IN 2024, VERSITI RESEARCHERS PUBLISHED 122 PEER-REVIEWED MANUSCRIPTS WITH 45 FEATURING VBRI FACULTY AS LEAD OR SENIOR AUTHORS, INCLUDING 5 PUBLICATIONS IN JOURNALS WITH IMPACT FACTORS EXCEEDING 30. 7 IN JOURNALS WITH IMPACT FACTORS BETWEEN 20 AND 30, AND 17 IN JOURNALS WITH IMPACT FACTORS BETWEEN 10 AND 20. VERSITI'S RESEARCH SPANS 5 MAJOR PROGRAMS: TRANSFUSION MEDICINE, VASCULAR BIOLOGY, AND CELLULAR THERAPY; THROMBOSIS AND (CONTINUED IN SCHEDULE O) HEMOSTASIS; STEM CELL BIOLOGY AND HEMATOPOIESIS; IMMUNOLOGY; AND TRANSLATIONAL HEMATOLOGY. VERSITI'S RESEARCH GRANT TEAMS PROCESSED APPROXIMATELY $41M IN NEW MULTI-YEAR GRANTS AND SUBMITTED 112 PROPOSALS TOTALING $140.13M IN 2024. VERSITI ALSO LEADS THROUGH COLLABORATIVE BLOOD SCIENCE INITIATIVES SUCH AS IN VENUS (VENOUS THROMBOEMBOLISM NETWORK US) AND REDS-IV-P (RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY), NATIONAL PROGRAMS ADVANCING THROMBOSIS TREATMENT AND BLOOD TRANSFUSION SAFETY. OPERATING IN AN 82,000 SQUARE-FOOT FACILITY, VERSITI IS HOME TO 213 RESEARCH STAFF, INCLUDING 35 INVESTIGATORS AND 22 RESEARCH SCIENTISTS, IN 2024. EDUCATIONAL INITIATIVES INCLUDE GRADUATE TRAINING, RESEARCH SYMPOSIA, AND COLLABORATIVE PARTNERSHIPS IN THE MILWAUKEE REGIONAL MEDICAL CENTER, SUCH AS THE MRMC HEMATOLOGY BIOREPOSITORY, WHICH PROVIDES ANNOTATED BIOLOGICAL SAMPLES FOR BIOMARKER DISCOVERY FOR CLINICAL PARTNERS THROUGHOUT CAMPUS.
- $83.2 million spent. MSI:THE VERSITI MEDICAL SERVICES INSTITUTE (MSI) ADVANCES PATIENT CARE THROUGH SPECIALIZED TREATMENT AND TRANSLATIONAL RESEARCH THAT BRIDGES CLINICAL MEDICINE AND LABORATORY SCIENCE, FOSTERING COLLABORATION BETWEEN PHYSICIAN-SCIENTISTS AND BASIC RESEARCHERS TO ACCELERATE MEDICAL DISCOVERIES. ESTABLISHED IN 2009 AND SUPPORTED BY VERSITI AND THE VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, MSI ENABLES PHYSICIANS TO DEDICATE PROTECTED TIME TO CLINICAL RESEARCH WHILE MAINTAINING PATIENT CARE RESPONSIBILITIES. IN 2024, VERSITI PHYSICIAN-SCIENTISTS PERFORMED 3,686 THERAPEUTIC PROCEDURES. AS PART OF VERSITI'S MISSION TO ADVANCE EVIDENCE-BASED MEDICINE, MSI OPERATES THE CLINICAL TRIALS & RESEARCH OFFICE (CTRO) TO CONDUCT FDA-REGULATED CLINICAL STUDIES IN SPECIALIZED AREAS INCLUDING ALLOIMMUNE PLATELET DISORDERS, TRANSFUSION-INDUCED ACUTE LUNG INJURY, AND DRUG-INDUCED BLOOD DISORDERS. THROUGH MENTORSHIP, PROTECTED RESEARCH TIME, AND COLLABORATIVE INFRASTRUCTURE, MSI PROVIDES DEEP CLINICAL EXPERTISE AND TRANSFORMS CLINICAL QUESTIONS INTO SCIENTIFIC DISCOVERIES THAT BENEFIT PATIENTS WITH BLOOD DISORDERS NATIONWIDE.DONOR TESTING:THE VERSITI DONOR TESTING LABORATORY (DTL) PROVIDES INFECTIOUS DISEASE TESTING TO DETERMINE DONOR SUITABILITY AND PRODUCT SAFETY FOR ORGANS, TISSUES, HEMATOPOIETIC STEM CELLS, AND CORD BLOOD. THE DTL OFFERS NUCLEIC ACID TESTING, ANTIBODY SCREENING, AND CONFIRMATORY TESTING FOR MANY DIFFERENT DISEASE STATES. AS PART OF VERSITI'S MISSION TO MAINTAIN THE SAFEST POSSIBLE BLOOD SUPPLY, DONOR TESTING OPERATIONS CONDUCT MANDATORY SCREENING FOR TRANSFUSION-TRANSMISSIBLE INFECTIONS AS REQUIRED BY FDA REGULATIONS. THE DTL UTILIZES STATE-OF-THE-ART NUCLEIC ACID TESTING (NAT) TECHNOLOGY AND SEROLOGICAL METHODS TO DETECT INFECTIOUS AGENTS. VERSITI'S DTL SUPPORTS BLOOD COLLECTION ACTIVITIES ACROSS VERSITI'S ENTIRE GEOGRAPHIC FOOTPRINT WHILE MAINTAINING RIGOROUS QUALITY STANDARDS AND REGULATORY COMPLIANCE. VERSITI'S DONOR TESTING SERVICES STRENGTHEN THE NATIONAL BLOOD SUPPLY INFRASTRUCTURE. BY ENSURING COMPREHENSIVE DONOR SCREENING, VERSITI PROTECTS PATIENTS WHO DEPEND ON SAFE BLOOD TRANSFUSIONS, STRENGTHENS THE NATIONAL BLOOD SUPPLY, AND SUPPORTS THE BROADER PUBLIC HEALTH MISSION OF MAINTAINING CONFIDENCE IN A HIGH-QUALITY BLOOD SUPPLY.DIAGNOSTIC LABS:VERSITI SERVES PATIENTS, PHYSICIANS, AND HOSPITALS BY PROVIDING COMPREHENSIVE CLINICAL DIAGNOSTIC TESTING SERVICES THAT SUPPORT ACCURATE DIAGNOSIS, TREATMENT MONITORING, AND PATIENT CARE ACROSS MULTIPLE MEDICAL SPECIALTIES. AS PART OF VERSITI'S MISSION TO ADVANCE HEALTHCARE THROUGH LABORATORY EXCELLENCE, THE DIAGNOSTIC LABORATORIES DELIVER SPECIALIZED TESTING SERVICES INCLUDING HEMATOLOGY, COAGULATION, IMMUNOHEMATOLOGY, INFECTIOUS DISEASE, MOLECULAR DIAGNOSTICS, FLOW CYTOMETRY, AND REFERENCE LABORATORY SERVICES. DURING 2024, VERSITI CONDUCTED 148,545 DIAGNOSTIC TESTING SERVICES FOR HOSPITALS, PHYSICIAN OFFICES, AND REFERENCE LABORATORIES. VERSITI'S DIAGNOSTIC LABORATORIES MAINTAIN STATE-OF-THE-ART INSTRUMENTATION AND RIGOROUS QUALITY ASSURANCE PROGRAMS TO ENSURE ACCURATE, TIMELY RESULTS THAT GUIDE CLINICAL DECISION-MAKING AND IMPROVE PATIENT OUTCOMES. THE LABORATORIES PROVIDE SPECIALIZED EXPERTISE IN BLOOD-RELATED DISORDERS, OFFERING ADVANCED TESTING CAPABILITIES INCLUDING PLATELET FUNCTION ANALYSIS, COAGULATION STUDIES, RED BLOOD CELL ANTIGEN TYPING, AND COMPLEX IMMUNOHEMATOLOGY WORKUPS THAT CONFIRM AND ENSURE TRANSFUSION SAFETY. VERSITI'S DIAGNOSTIC LABORATORIES SERVE AS A VITAL HEALTHCARE INFRASTRUCTURE RESOURCE, PROVIDING 24/7 TESTING SUPPORT FOR EMERGENCY DEPARTMENTS AND CRITICAL CARE UNITS. THROUGH COMPREHENSIVE DIAGNOSTIC TESTING SERVICES, ADVANCED LABORATORY EXPERTISE, AND COMMITMENT TO QUALITY, VERSITI'S DIAGNOSTIC LABORATORIES STRENGTHEN THE HEALTHCARE SYSTEM BY ENABLING ACCURATE DIAGNOSIS AND OPTIMAL PATIENT CARE ACROSS THE STATE.ORGAN AND TISSUE:VERSITI ORGAN AND TISSUE OPERATES AS SOUTHEASTERN WISCONSIN'S FEDERALLY DESIGNATED ORGAN PROCUREMENT ORGANIZATION, COORDINATING ORGAN AND TISSUE DONATION TO SAVE AND HEAL LIVES THROUGHOUT THE STATE. ROOTED IN VERSITI'S MISSION TO ADVANCE PUBLIC HEALTH, THE ORGANIZATION FACILITATES THE GENEROUS GIFT OF DONATION BY WORKING WITH DONOR FAMILIES, HOSPITALS, AND TRANSPLANT CENTERS TO ENSURE ORGANS AND TISSUES REACH PATIENTS IN NEED. IN 2024, VERSITI ORGAN AND TISSUE COORDINATED 394 ORGAN TRANSPLANTS FROM 606 MUSCULOSKELETAL DONORS. THE ORGANIZATION PROVIDES 24/7 COORDINATION SERVICES, FAMILY SUPPORT, AND CLINICAL EXPERTISE THROUGHOUT THE DONATION PROCESS. VERSITI'S DONATION COORDINATORS AND CLINICAL STAFF WORK ALONGSIDE HOSPITAL TEAMS TO IDENTIFY POTENTIAL DONORS, SUPPORT GRIEVING FAMILIES, AND ENSURE OPTIMAL ORGAN AND TISSUE RECOVERY. THROUGH COMMUNITY EDUCATION PROGRAMS LIKE DONATE LIFE MONTH IN APRIL, VERSITI PROMOTES DONATION AWARENESS AND SUPPORTS WISCONSIN FAMILIES WHO CHOOSE THE HEALING PATH OF DONATION. BY FACILITATING ORGAN AND TISSUE DONATION, VERSITI ORGAN AND TISSUE TRANSFORMS TRAGEDY INTO HOPE, ENABLING ONE DONOR TO SAVE UP TO EIGHT LIVES THROUGH ORGAN DONATION AND HEAL DOZENS MORE THROUGH TISSUE DONATION.VCTS:VERSITI CLINICAL TRIALS SERVICES (VCTS) PROVIDES COMPREHENSIVE CLINICAL RESEARCH SERVICES TO PHARMACEUTICAL SPONSORS, BIOTECHNOLOGY COMPANIES, AND ACADEMIC INSTITUTIONS CONDUCTING CLINICAL STUDIES IN HEMATOLOGY, TRANSFUSION MEDICINE, ONCOLOGY, IMMUNOLOGY, CELL AND GENE THERAPY, AND ORPHAN AND RARE DISEASES. AS PART OF VERSITI'S MISSION TO ADVANCE MEDICAL SCIENCE, VCTS OFFERS SPECIALIZED LABORATORY SERVICES, INSTITUTIONAL REVIEW BOARD (IRB) OVERSIGHT, BIOSPECIMEN COLLECTION AND MANAGEMENT, PROJECT MANAGEMENT, AND REGULATORY SUPPORT TO ENSURE SAFE AND COMPLIANT STUDIES. VCTS LEVERAGES VERSITI'S UNIQUE EXPERTISE IN BLOOD SCIENCE AND LABORATORY DIAGNOSTICS TO SUPPORT COMPLEX TRIALS REQUIRING SPECIALIZED TESTING CAPABILITIES. THE PROGRAM MAINTAINS RIGOROUS QUALITY STANDARDS AND REGULATORY COMPLIANCE WHILE PROVIDING INNOVATIVE SOLUTIONS FOR COMPLEX CLINICAL RESEARCH CHALLENGES. THR
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since July 1994.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.